D. E. Shaw & Co., Inc. Aerie Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $28,174 - $67,362	-4,423 Reduced 1.78%	243,976 $3.69 Million
Q2 2022 Aug 15, 2022	BUY	$4.95 - $9.16 $930,100 - $1.72 Million	187,899 Added 310.58%	248,399 $1.86 Million
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $341,220 - $592,900	60,500 New	60,500 $551,000
Q3 2021 Nov 15, 2021	SELL	$11.32 - $16.63 $242,881 - $356,813	-21,456 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $325,272 - $407,020	21,456 New	21,456 $344,000
Q1 2020 May 15, 2020	SELL	$11.84 - $25.52 $111,745 - $240,857	-9,438 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$17.72 - $25.1 $2.43 Million - $3.45 Million	-137,331 Reduced 93.57%	9,438 $228,000
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $2.7 Million - $4.11 Million	146,769 New	146,769 $2.82 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.